Dr. Bosse Discusses Bone-Targeted Agents in RCC | OncLive

Dr. Bosse Discusses Bone-Targeted Agents in RCC

March 13, 2018

Dominick Bosse, MD, fellow, Dana-Farber Cancer Institute, discusses bone-targeted agents for patients with renal cell carcinoma (RCC).

Dominick Bosse, MD, fellow, Dana-Farber Cancer Institute, discusses bone-targeted agents for patients with renal cell carcinoma (RCC).

Bone-targeted agents are used in RCC but are a part of supportive care, says Bosse. It is controversial because part of the data come from a small subset of heterogeneous larger trials that were carried on before the era of targeted therapy. Now that there are so many options for the treatment of patients with RCC, it is harder to determine which regimen is the best choice, adds Bosse.

Bone-targeted agents are still used but need to be used carefully, particularly when combined with VEGF-targeted agents, as they can increase side effects. It is reserved for patients with bone pain or a higher burden of bone disease.


x